[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$pfes
$PFE's acquisition of Matsera is generating buzz, but concerns linger about its market position and the withdrawal of a product. Investors are weighing the risks and rewards of the deal amidst a competitive market for pharmaceutical companies.
About $pfes
Social media analysis of Pfizer, Inc. ($PFE) and related topics.
Engagements: X #
Engagements 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: XXX
1 Week: XXXXX -XX%
1 Month: XXXXX -XX%
1-Year High: XXXXXX on 2025-07-22
1-Year Low: X on 2025-05-12
| Social Network | X |
|---|---|
| Engagements | X |
Mentions: X #
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
1 Month: X -XX%
1-Year High: X on 2025-04-30
1-Year Low: X on 2025-04-28
| Social Network | X |
|---|---|
| Mentions | X |
Creators: X #
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $pfes in the last XX hours which is down XX% from X in the previous XX hours
Daily Average: X
1 Month: X -XX%
1-Year High: X on 2025-05-01
1-Year Low: X on 2025-04-28
Sentiment: % #
Sentiment 24-Hour Time-Series Raw Data
Current Value: %
Daily Average: XX%
1-Year High: XXX% on 2025-04-29
1-Year Low: XX% on 2025-10-09
Top assets mentioned In the posts about $pfes in the last XX hours
Metsera, Inc. Common Stock (MTSR)
Top topics mentioned In the posts about $pfes in the last XX hours
$mtsr, $30share, $39share, $50share, approved, $zlab, $gmab, china
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Evolution of $PFE's offers to $MTSR : $XX $XX Jun X : $30/share Aug XX : $39/share ($34 cash + $X CVR) Sept X : $50/share ($40 cash + $XX CVR) Sept XX : $60/share ($45 cash + $XX CVR) Sept XX : $65/share ($45 cash + $XX CVR) Sept XX : $70/share ($47.50 cash + $XXXXX CVR) $VKTX"
X Link @MeadowCapital 2025-10-06T14:41Z 1239 followers, 4963 engagements
"$ZLAB TIVDAK (tisotumab vedotin-tftv) approved in HK This is $GMAB and $PFE's ADC for recurrent or metastatic cervical cancer Approved by the FDA is the US in Apr 2024 Now approved in HK Under review in mainland China Zai Lab has exclusive license from Pfizer in Greater China (CN HK TW MO) 🥼🔬🧫🧪🦠🧬💻🧑🔬🤒🌡💉🩸🩹💊😷🩺🏥⚕"
X Link @TohJah7809 2025-09-06T09:05Z 2059 followers, XXX engagements